Healthcare

Algorae Pharmaceuticals (ASX:1AI) has risen 9.09% as the company increasingly presents two separate value drivers: a pharmaceutical supplyBusinessdesigned to generate nearer-term revenue, and an AI drug-discovery platform aimed at longer-term licensing and development upside. July brought milestones on both sides, with a NSW Health …

Pro Medicus Limited (ASX:PME) traded lower on Monday, placing the medical imaging technology company among the top S&P/ASX 200 decliners on 17 August 2026.

Neuren Pharmaceuticals Limited (ASX:NEU) traded lower on Monday, although the biotechnology stock continued to show a positive longer-term return.

Paragon Care (ASX:PGC) enters its FY26 results with investors focused on whether its healthcare distribution transformation is beginning to deliver consistent operating performance. The company has expanded through acquisitions across medical supplies, pharmaceuticals and logistics, creating a larger healthcare platform across Australia, New Zealand …

Mach7 Technologies (ASX:M7T) enters its FY26 reporting season with investors assessing whether a year of revenue pressure has created a stronger operating foundation. The Melbourne-based medical imaging software company has faced lowerCapitaldeal conversion, but it has maintained positive operating cash flow, a debt-freeBalance Sheetand …

Microba Life Sciences (ASX:MAP) enters the next phase of its commercial development after FY26 results showed significant growth in its core testing business. The Brisbane-based biotechnology company has been working to transition from lower-value contract activity toward clinician-ordered microbiome diagnostics, with core testing revenue …

Monash IVF Group (ASX:MVF) enters its next phase focused on rebuilding operational performance and confidence following a difficult period. The fertility services provider faced clinical governance challenges,Leadershipchanges and weaker domestic volumes, which contributed to a decline in first-half FY26 earnings. The company is now …